These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28274233)

  • 1. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.
    Stinton C; Geppert J; Freeman K; Clarke A; Johnson S; Fraser H; Sutcliffe P; Taylor-Phillips S
    Orphanet J Rare Dis; 2017 Mar; 12(1):48. PubMed ID: 28274233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
    la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E
    Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
    Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
    Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine.
    Metz TF; Mechtler TP; Merk M; Gottschalk A; Lukačin R; Herkner KR; Kasper DC
    Clin Chim Acta; 2012 Aug; 413(15-16):1259-64. PubMed ID: 22521492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.
    De Jesús VR; Adam BW; Mandel D; Cuthbert CD; Matern D
    Mol Genet Metab; 2014; 113(1-2):67-75. PubMed ID: 25066104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone.
    Sander J; Janzen N; Peter M; Sander S; Steuerwald U; Holtkamp U; Schwahn B; Mayatepek E; Trefz FK; Das AM
    Clin Chem; 2006 Mar; 52(3):482-7. PubMed ID: 16439608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program.
    la Marca G; Malvagia S; Funghini S; Pasquini E; Moneti G; Guerrini R; Zammarchi E
    Rapid Commun Mass Spectrom; 2009 Dec; 23(23):3891-3. PubMed ID: 19902423
    [No Abstract]   [Full Text] [Related]  

  • 8. Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I.
    Adam BW; Lim TH; Hall EM; Hannon WH
    Clin Chem; 2009 Dec; 55(12):2207-13. PubMed ID: 19850631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS.
    Al-Dirbashi OY; Rashed MS; Jacob M; Al-Ahaideb LY; Al-Amoudi M; Rahbeeni Z; Al-Sayed MM; Al-Hassnan Z; Al-Owain M; Al-Zeidan H
    Biomed Chromatogr; 2008 Nov; 22(11):1181-5. PubMed ID: 18651606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.
    Magera MJ; Gunawardena ND; Hahn SH; Tortorelli S; Mitchell GA; Goodman SI; Rinaldo P; Matern D
    Mol Genet Metab; 2006 May; 88(1):16-21. PubMed ID: 16448836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newborn screening for hepatorenal tyrosinemia-I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program.
    Zytkovicz TH; Sahai I; Rush A; Odewale A; Johnson D; Fitzgerald E; Britton D; Eaton RB
    Clin Biochem; 2013 May; 46(7-8):681-4. PubMed ID: 23462696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
    Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
    Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots.
    Allard P; Grenier A; Korson MS; Zytkovicz TH
    Clin Biochem; 2004 Nov; 37(11):1010-5. PubMed ID: 15498530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant increase of succinylacetone within the first 12 h of life in hereditary tyrosinemia type 1.
    Schlump JU; Mayatepek E; Spiekerkoetter U
    Eur J Pediatr; 2010 May; 169(5):569-72. PubMed ID: 19813022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia.
    Weigel JF; Janzen N; Pfäffle RW; Thiery J; Kiess W; Ceglarek U
    J Inherit Metab Dis; 2007 Aug; 30(4):610. PubMed ID: 17694358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots.
    Turgeon C; Magera MJ; Allard P; Tortorelli S; Gavrilov D; Oglesbee D; Raymond K; Rinaldo P; Matern D
    Clin Chem; 2008 Apr; 54(4):657-64. PubMed ID: 18281422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newborn screening for Tyr-I: two years' experience of the New York State program.
    Morrissey MA; Sunny S; Fahim A; Lubowski C; Caggana M
    Mol Genet Metab; 2011 Jun; 103(2):191-2. PubMed ID: 21441051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newborn Screening for Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase and Mitochondrial Trifunctional Protein Deficiencies Using Acylcarnitines Measurement in Dried Blood Spots-A Systematic Review of Test Accuracy.
    Stinton C; Fraser H; Geppert J; Johnson R; Connock M; Johnson S; Clarke A; Taylor-Phillips S
    Front Pediatr; 2021; 9():606194. PubMed ID: 33816395
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of factors influencing accuracy in the analysis of succinylacetone in dried blood spots.
    Peng M; Liu L; Peng L
    Clin Chim Acta; 2012 Aug; 413(15-16):1265-9. PubMed ID: 22522056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.
    Geppert J; Stinton C; Freeman K; Fraser H; Clarke A; Johnson S; Sutcliffe P; Taylor-Phillips S
    Orphanet J Rare Dis; 2017 Sep; 12(1):154. PubMed ID: 28893311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.